Stocks in play: Numinus Wellness Inc.
Announced that its research site, Cedar Clinical Research, has been chosen as one of multiple sites for Cybin's Phase 3 pivotal, multinational clinical trial of CYB003 for the adjunctive treatment of Major Depressive Disorder. Numinus Wellness Inc. shares T.NUMI are trading unchanged at $0.07.
Read:
Artificial Intelligence Emerges as a Game Changer for Data Center Management
Biotech Breakthroughs Spearhead Fight Against Rising Breast Cancer Cases
Global Efforts Intensify to Address Surging Young Adult Colorectal and Anal Cancer Rates
Harnessing AI's $4.4 Trillion Potential Reshapes the Tech Industry Landscape
Critical Push for US Domestic Nickel Needed to Halt Total Reliance on Questionable Foreign Imports